Day One Biopharmaceuticals, Inc. (DAWN)

Market Cap	666.97M
Revenue (ttm)	161.92M
Net Income (ttm)	-69.08M
Shares Out	101.36M
EPS (ttm)	-0.71
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,289,102
Open	6.65
Previous Close	6.45
Day's Range	6.52 - 7.02
52-Week Range	6.41 - 18.07
Beta	-1.24
Analysts	Strong Buy
Price Target	31.57 (+379.79%)
Earnings Date	May 6, 2025

About DAWN

Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company’s lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage. It also developing DAY301, which is in phase I c...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 27, 2021
• Employees: 181
• Stock Exchange: NASDAQ
• Ticker Symbol: DAWN
• Website: https://dayonebio.com

Analyst Forecast

According to 7 analysts, the average rating for DAWN stock is "Strong Buy." The 12-month stock price forecast is $31.57, which is an increase of 379.79% from the latest price.

Price Target

$31.57

(379.79% upside)

Analyst Consensus: Strong Buy